[DOI] [PubMed] [Google Scholar] 98.McCulloch K., Litherland G.J., Rai T.S
In pooled Zepbound weight-reduction trials, nausea was reported in 25% to 29% of treatment groups across labeled doses compared with 8% receiving placebo
438,439 GLP-1 can also enhance endothelial function by promoting the production of NO, possibly through activating eNOS, thereby affecting vasodilation, anti-inflammatory actions, and anti-atherosclerosis
GLP-1 is a crucial incretin hormone that regulates blood glucose, promotes satiety, and has become a therapeutic target in managing type 2 diabetes and obesity
45 All studies that demonstrated a reduction in MACE on GLP-1RA therapy consistently involved patients with T2D
The important framing: these are ingredient-level findings from oral supplementation studies, not claims about LeviaPatch's specific product performance